Advertisement

Pharmaceutical Medicine

, Volume 22, Issue 6, pp 389–400 | Cite as

Journal Watch

Update
  • 20 Downloads

Contents

  • Abstract

  • 1. Controlled Trials and Risk of Harm

  • 2. Funding a Clinical Trial: The Perspective of a Medicines Funder

  • 3. Drug Delivery Systems in Children

  • 4. Measuring US Pharmaceutical Industry R&D Spending

  • 5. An Automated Standardized System for Managing Adverse Events in Clinical Research Networks

  • 6. Disposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery

  • 7. Regulatory Aspects of Pharmacokinetic Profiling in Special Populations: A European Perspective

  • 8. Unrelated Medical Costs in Life-Years Gained

  • 9. Clinical Application of Array-Based Comparative Genomic Hybridization for the Identification of Prognostically Important Genetic Alterations in Chronic Lymphocytic Leukaemia

  • 10. Molecular Signatures of Cardiovascular Disease Risk: Potential for Test Development and Clinical Application

  • 11. Biomarkers for Alzheimer’s Disease in Cerebrospinal Fluid, Urine, and Blood

  • 12. Pharmacogenetics of Major Depression: Insights from Level 1 of the Sequenced...

References

Reference

  1. Edwards RI. Controlled trials and risk of harm [editorial]. Drug Saf 2008; 31 (11): 961–3PubMedCrossRefGoogle Scholar

Reference

  1. Alsop P, Metcalfe S, Evans J. Funding a clinical trial: the perspective of a medicines funder. Pharmacoeconomics 2008; 26 (10): 811–4PubMedCrossRefGoogle Scholar

Reference

  1. Lowis S. Drug delivery systems in children. Pediatr Drugs 2008; 10 (6): 351–5CrossRefGoogle Scholar

Reference

  1. Golec J, Vernon J. Measuring US Pharmaceutical industry R&D spending. Pharmacoeconomics 2008; 26 (12): 1005–17PubMedCrossRefGoogle Scholar

Reference

  1. Richesson RL, Malloy JF, Paulus K, et al. An automated standardized system for managing adverse events in clinical research networks. Drug Saf 2008; 31 (10): 807–22PubMedCrossRefGoogle Scholar

Reference

  1. Aliabadi HM, Shahin M, Brocks DR, et al. Disposition of drugs in block copolymer efmicelle delivery systems: from discovery to recovery. Clin Pharmacokinet 2008; 47 (10): 619–34PubMedCrossRefGoogle Scholar

Reference

  1. Edholm M, Gil Berglund E, Salmonson T. Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective. Clin Pharmacokinet 2008; 47 (11): 693–701PubMedCrossRefGoogle Scholar

Reference

  1. Rappange DR, van Baal PHM, van Exel NJA, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26 (10): 815–30PubMedCrossRefGoogle Scholar

Reference

  1. Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. Mol Diag Ther 2008; 12 (5): 271–80CrossRefGoogle Scholar

Reference

  1. Schunkert H, Konig IR, Erdmann J. Molecular signatures of cardiovascular disease risk: potential for test development and clinical application. Mol Diag Ther 2008; 12 (5): 281–7CrossRefGoogle Scholar

Reference

  1. Lonneborg A. Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood. Mol Diag Ther 2008; 12 (5): 307–20CrossRefGoogle Scholar

Reference

  1. Lekman M, Paddock S, McMahon FJ. Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Mol Diag Ther 2008; 12 (5): 321–30CrossRefGoogle Scholar

Reference

  1. Blanchet B, Jullien V, Vinsonneau C, et al. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 47 (10): 635–54PubMedCrossRefGoogle Scholar

Reference

  1. Zhang F, Pasumarthi KBS. Embryonic Stem cell transplantation: promise and progress in the treatment of heart disease. Biodrugs 2008; 22 (6): 361–74PubMedCrossRefGoogle Scholar

Reference

  1. Aires da Silva F, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. Biodrugs 2008; 22 (5): 301–14PubMedCrossRefGoogle Scholar

Reference

  1. Dressman JB, Thelen K, Jantratid E. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 2008; 47 (10): 655–67PubMedCrossRefGoogle Scholar

Reference

  1. Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R D 2008; 9 (6): 351–68PubMedCrossRefGoogle Scholar

Reference

  1. Hausner E, Fiszman ML, Hanig J, et al. Long-term consequences of drugs on the paediatric cardiovascular system. Drug Saf 2008; 31 (12): 1083–96PubMedGoogle Scholar

Reference

  1. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 2008; 31 (10): 823–37PubMedCrossRefGoogle Scholar

Reference

  1. Ruchlin HS, Insinga RP. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 2008; 26 (11): 925–35PubMedCrossRefGoogle Scholar

Reference

  1. Perry LCA, Jones TD, Baker MP. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 2008; 9 (6): 385–96PubMedCrossRefGoogle Scholar

Reference

  1. Blair ED. Assessing the value-adding impact of diagnostic-type tests on drug development and marketing. Mol Diag Ther 2008; 12 (5): 331–7CrossRefGoogle Scholar

Reference

  1. Wijnen PAHM, Drent M, Nelemans PJ, et al. Role of cytochrome P450 Polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Saf 2008; 31 (12): 1125–34PubMedGoogle Scholar

Reference

  1. Eguale T, Tamblyn R, Winslade N, et al. Detection of adverse drug events and other treatment outcomes using an electronic prescribing system. Drug Saf 2008; 31 (11): 1005–16PubMedCrossRefGoogle Scholar

Reference

  1. Hopstadius J, Noren GN, Bate A, et al. Impact of stratification on adverse drug reaction surveillance. Drug Saf 2008; 31 (11): 1035–48PubMedCrossRefGoogle Scholar

Reference

  1. Verdel BM, van Puijenbroek EP, Souverein PC, et al. Drug-related nephrotoxic and ototoxic reactions: a link through a predictive mechanistic commonality. Drug Saf 2008; 31 (10): 877–84PubMedCrossRefGoogle Scholar

Reference

  1. Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008; 47 (11): 743–52PubMedCrossRefGoogle Scholar

Reference

  1. Ohno Y, Hisaka A, Ueno M, et al. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008; 47 (10): 669–80PubMedCrossRefGoogle Scholar

Reference

  1. Lau DT, Briesacher BA, Mercaldo ND, et al. Older patients’ perceptions of medication importance and worth: an exploratory pilot study. Drugs Aging 2008; 25 (12): 1061–75PubMedCrossRefGoogle Scholar

Reference

  1. Gooi M, Bell CM. Differences in generic drug prices between the US and Canada. Appl Health Econ Health Pol 2008; 6 (1): 19–26CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations